Michiel H. Strijbos

Brasschaat, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial.

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial.

Journal: European urology oncology
Published: July 28, 2025

The unjustified fear of erdafitinib-induced central serous retinopathy.

The unjustified fear of erdafitinib-induced central serous retinopathy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 03, 2025

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.

Journal: European urology oncology
Published: January 22, 2025

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Journal: Nature medicine
Published: August 28, 2024

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Journal: Nature medicine
Published: January 13, 2024

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.

Journal: The Lancet. Oncology
Published: November 08, 2022

Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data.

Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data.

Journal: ESMO open
Published: November 04, 2022

Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with Cancer.

Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with Cancer.

Journal: Oncology research and treatment
Published: October 21, 2022

Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.

Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.

Journal: ESMO open
Published: August 30, 2022

New targets, new hopes.

New targets, new hopes.

Journal: ESMO open
Published: January 28, 2022

Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic Therapy.

Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic Therapy.

Journal: European urology
Published: December 21, 2021

11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentation.

11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentation.

Journal: ESMO open
Published: November 09, 2021
Showing 1-12 of 31

Last Updated: 09/26/2026